AstraZeneca Acknowledges Rare Clotting Risk with Covishield, Stresses Vaccine Safety

May 2, 2024
AstraZeneca Acknowledges Rare Clotting Risk with Covishield, Stresses Vaccine Safety
  • AstraZeneca acknowledges a possible link between its Covishield Covid vaccine and the rare condition Thrombosis with Thrombocytopenia Syndrome (TTS).

  • Despite the potential link, the incidence of TTS is considered rare, particularly among Indians and South Asians, and the vaccine's benefits are deemed to outweigh the risks.

  • The World Health Organization maintains that vaccines are largely safe with typically minor, temporary side effects.

  • A class action lawsuit has been initiated against AstraZeneca; however, the company maintains that safety is a primary concern and that vaccines meet rigorous regulatory standards.

  • The Healthy Indian Project aims to provide accurate vaccine information and dispels myths about vaccine toxicity.

  • People are encouraged to be alert for TTS symptoms and to seek medical advice for any adverse reactions, though current recommendations suggest no need for immunization for most, with certain highly immune-compromised individuals considering newer vaccine options.

Summary based on 17 sources


Get a daily email with more World News stories

More Stories